BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

Coming at the opioid crisis from two different angles, NIH’s National Institute on Drug Abuse and Alkermes plc have concluded that ending the epidemic will mean developing ways of getting medication to patients who fall...
BioCentury | Apr 4, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

...University ; Boston University School of Medicine Distillery Therapeutics Lysophospholipase 2 (LYPLA2; APT2) Ovarian cancer Aldehyde dehydrogenase...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Pan-ALDH1A inhibitor for ovarian cancer

...Next steps include testing the compound in combination with undisclosed immunotherapies in animal models. TARGET/MARKER/PATHWAY: Aldehyde dehydrogenase...
...Mich. email: buckanovichrj@mwri.magee.edu Claire Quang University of Michigan Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) Aldehyde dehydrogenase 1 family member A2 (ALDH1A2) Aldehyde dehydrogenase...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...doi:10.1016/j.chembiol.2018.09.005 CONTACT: E. Elizabeth Patton, University of Edinburgh, Edinburgh, U.K. email: e.patton@igmm.ed.ac.uk Jaime De Leon University of Edinburgh Aldehyde dehydrogenase...
BioCentury | Apr 28, 2017
Emerging Company Profile

Cutting cravings

...currently underserved by therapeutics, including alcohol abuse and cocaine and opioid addiction. The compound inhibits aldehyde dehydrogenase...
...said Amygdala is seeking additional capital. COMPANY PROFILE Amygdala Neurosciences Inc. Palo Alto, Calif. Technology: Aldehyde dehydrogenase...
...addiction." CNS & Neurological Disorders - Drug Targets (2015) Yao, L., et. al. "Inhibition of aldehyde dehydrogenase-2...
BioCentury | Feb 17, 2017
Company News

Gilead, Amygdala deal

...Phase II trials this year of GS-6637 in alcohol and cocaine addiction. GS-6637 is an aldehyde dehydrogenase...
...City, Calif. Amygdala Neurosciences Inc. , Palo Alto, Calif. Business: Neurology Chris Lieu GS-6637 Amygdala Neurosciences Inc. Gilead Sciences Inc. Aldehyde dehydrogenase...
BioCentury | Feb 16, 2017
Company News

Amygdala acquires addiction candidate from Gilead

...this year of the candidate to treat cocaine and alcohol use disorders. GS-6637 is an aldehyde dehydrogenase...
BioCentury | Nov 15, 2016
Distillery Therapeutics

Cancer

...treatment. Next steps could include identifying and testing FOXD1 inhibitors. TARGET/MARKER/PATHWAY: Forkhead box D1 (FOXD1); aldehyde dehydrogenase...
...Ichiro Nakano, University of Alabama at Birmingham, Birmingham, Ala. email: inakano@uabmc.edu Steven Hochhauser University of Alabama at Birmingham Aldehyde dehydrogenase...
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-30a (miR-30a)

...and diphenhydramine hydrochloride in CD4+ T cells from MS patients. The generic acetaldehyde dehydrogenase ( ALDH...
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1); cytochrome P450 26A1 (CYP26A1; CP26)

...has rambazole , a topical CYP26A1 inhibitor, in Phase II testing to treat acne. TARGET/MARKER/PATHWAY: Aldehyde dehydrogenase...
Items per page:
1 - 10 of 73